The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Steven M. Horwitz, Tatyana A. Feldman, Brian T. Hess, Michael S Khodadoust, Youn H. Kim, Javier Munoz, Manish R Patel, Tycel J. Phillips, Stephen D. Smith, Sonali M. Smith, Ryan A. Wilcox, Andrew Steele, Anjali Pandey, Matt R Birrell, Janet M. Leeds, Pamela B. Conley, Glenn Michelson, Gregory P. Coffey, John T Curnutte, Paul A. Hamlin
Institutions: Memorial Sloan Kettering Cancer Center, Hackensack University Medical Center, Medical University of South Carolina, MUSC Hollings Cancer Center, Stanford Medicine, Banner MD Anderson Cancer Center, Sarah Cannon, Florida Cancer Specialists & Research Institute, U-M Rogel Cancer Center, Seattle Cancer Care Alliance, University of Washington, University of Chicago, Portola Pharmaceuticals (United States)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2899473088